Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 864 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
55
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 51 more
Conditions
ADHD
Interventions
OROS-MPH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Oppositional Defiant, Conduct Disorder
Interventions
Mobile Health Applictaion
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
7 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Homework, Organization, and Planning Skills (HOPS) Intervention, Homework Support Intervention (HSI)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
11 Years to 15 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Active, not recruiting Not applicable Interventional

Parent-Educator Action Response

NCT07203014
Conditions
Attention Deficit and Disruptive Behavior Disorders
Interventions
Parent-Educator Action Response (PEAR), Daily Report Card
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
School Readiness, Developmental Delays
Interventions
Early Intervention Foster Care (EIFC)
Behavioral
Lead sponsor
Oregon Social Learning Center
Other
Eligibility
3 Years to 6 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Eugene, Oregon
Completed Phase 3 Interventional

PRC-063 in Adolescent ADHD

NCT02139111
Conditions
ADHD
Interventions
Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 85 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
12 Years to 17 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 25 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, Delaware
Completed Not applicable Interventional Results available

Improving ADHD Behavioral Care

NCT03628781
Conditions
ADHD
Interventions
Behavioral tools integrated within mehealth for ADHD software, mehealth for ADHD
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 12 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Autism Spectrum Disorder, Attention Deficit/Hyperactivity Disorder, Developmental Delay
Interventions
Not listed
Lead sponsor
Thomas W. Frazier, Ph.D
Other
Eligibility
1 Year to 12 Years
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Attention Deficit Hyperactivity Disorder, Depressive Symptoms
Interventions
Behaviorally Enhancing Adolescents' Mood in Schools, Usual Care
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
14 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
College Park, Maryland
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Dothan, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Effect of Vyvanse on Driving in Young Adults With ADHD

NCT00801229
Conditions
Attention Deficit/Hyperactivity Disorder(ADHD)
Interventions
Vyvanse, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 24 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation

NCT05802680
Conditions
Attention Deficit Hyperactivity Disorder, Attention Difficulties, Attention Deficit, Cognitive Deficit, Wellness
Interventions
Transcranial photobiomodulation, Sham transcranial photobiomodulation
Device
Lead sponsor
Francisco Gonzalez-Lima, PhD
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Austin, Texas
Conditions
Disruptive Behavior Disorders
Interventions
Behavioral Parent Training
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 7 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
TRI102, Placebo
Drug · Other
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Newport Beach, California • Las Vegas, Nevada • Durham, North Carolina + 2 more
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
ADHD
Interventions
Little Flower Yoga For Kids
Behavioral
Lead sponsor
New York University
Other
Eligibility
5 Years to 7 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Pediatric Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Hialeah, Florida + 7 more
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride XR, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
8 Years to 15 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Meta-Cognitive Therapy, Supportive Therapy
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

NCT03834766
Conditions
ADHD
Interventions
AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
Conditions
Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Child Behavior Disorders, Attention Deficit Disorder With Hyperactivity, Disorders of Excessive Somnolence
Interventions
CPAP treatment, No CPAP treatment
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan